News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Defense Department Funds Next Phase of Stratatech Clinical Trial


10/8/2010 9:57:45 AM

MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that the Defense Department’s Armed Forces Institute of Regenerative Medicine (AFIRM) will fund the Phase IIb clinical trial of the company’s flagship StrataGraft® living human skin substitute tissue.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES